Intended Audience:
This symposium is designed for interventional cardiologists, cardiologists, cardiology program directors, and other healthcare providers caring for patients with acute cardiovascular disease.

Registration:
Enrollment for this webcast is complimentary, and clinicians are invited to view this CME-certified webcast and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:
Supported by an independent educational grant from The Medicines Company, Inc.

Accreditation Statement for Jointly-Sponsored Programs:
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:
The University of Massachusetts Medical School designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty and Provider Disclosure:
It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Faculty Disclosures:

A. Michael Lincoff, MD
Relationships with Industry Research Sponsors
Cleveland Clinic Cardiovascular Coordinating Center
Abraxis, Alexion Pharma, AstraZeneca, Atherogenics, Aventis, Biosense Webster, Biosite, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb (BMS), Cardionet, Centocor, Converge Medical Inc., Cordis, Dr. Reddy’s Laboratory, Edwards Lifesciences, Esperion, GE Medical, Genentech, Gilford, GSK, Guidant, J&J, Kensey-Nash, Lilly, Medicines Company, Medtronic, Merck, Mytogen, Novartis, Novo Nordisk, Orphan Therapeutics, P&G Pharma, Pfizer, Roche, Sankyo, Sanofi-Aventis, Schering-Plough, Scios, St. Jude Medical, Takeda, VasoGenix, Viacor

Peter B. Berger, MD, FACC
Grant/Research Support: Conor and Cardiokinetix
Honoraria: BMS, sanofi-aventis, Schering-Plough, Lilly and Daiichi/Sankyo
Consultant: Cordis/Johnson & Johnson, Boston Scientific and Biogen
Equity: Lumen, Inc.

E. Magnus Ohman MD, FRCPI, FACC
Research Grants: Berlex, sanofi-aventis, Schering-Plough Corporation, Bristol Meyer Squibb, and Millennium. Stockholder: Medtronic. Consultant: Response Biomedical, Liposcience, and Inovise Medical

Elliott M. Antman, MD, FACC, FAHA
Grant/Research Support: sanofi-aventis, Eli Lilly
Consultant: Eli Lilly

Program Faculty
A. Michael Lincoff, MD
Vice Chairman for Research
Department of Cardiovascular Medicine
Director, Cleveland Clinic Cardiovascular Coordinating Center
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve UniversityThe Cleveland Clinic Foundation
Cleveland, Ohio

Peter B. Berger, MD, FACC
Associate Chief for Clinical Research
Geisinger Hospitals and Clinics
Danville, Pennsylvania

E. Magnus Ohman MD, FRCPI, FACC
Professor of Medicine
Director, Program for Advanced Coronary Disease
Division of Cardiology
Duke University Medical Center
Durham, NC

 Elliott M. Antman, MD, FACC, FAHA
Professor of Medicine
Harvard Medical School
Director of the Coronary Care Unit (CCU)
Brigham and Women’s Hospital
Boston, MA

Educational Objectives:

• As a result of this session, cardiologists and related specialists will be able to assess and implement optimal antithrombotic strategies for patients with acute coronary syndromes (ACS).

• As a result of this session, attendees will understand the impact of specific pharmacologic agents on outcomes, including ischemic endpoints, bleeding, and mortality for patients with ACS.

• As a result of this session, attendees will be able to discuss the impact that new trials are likely to have on future management of patients with ACS.

• As a result of this session, attendees will learn to apply AHA/ACC/SCAI and other national guidelines in order to optimize therapy ACS.